Biosion Inc. has gained FDA clearance of its IND application for BSI-082, a novel anti-SIRPα monoclonal antibody (mAb) candidate.

Cytomx Therapeutics Inc. has received clearances from the FDA for IND applications for two conditionally activated Probody therapeutics.

NK Celltech Co. Ltd. has announced FDA clearance for a clinical trial of NK-010, a nongenetically modified allogeneic peripheral blood natural killer (NK) cell drug.

Aruna Bio Inc. has gained FDA clearance for its IND application for AB-126, enabling initiation of a phase Ib/IIa trial in acute ischemic stroke.

CSPC Pharmaceutical Group Ltd. has announced FDA approval of an IND application for JMT-106, a bispecific fusion protein drug, for glypican-3 (GPC3)-positive solid tumors.

Corbus Pharmaceuticals Holdings Inc. has obtained FDA clearance of its IND application for CRB-601, a TGF-β-blocking monoclonal antibody targeting the integrin αvβ8. Enrollment in a first-in-human phase I study will open in the first half of this year.